Titration of vaccine sera in the HT-PBNA using PSV of HPV types 16, 18, 31, 45, 52, 58 and BPV-1. A

<p>) Standard serum from Gardasil® vaccinated person. <b>B</b>) Cervarix® vaccine serum. <b>C</b>) Serum from a mouse immunized with L2 epitopes (amino acids 17–36) from HPV16 inserted in the capsid of adeno-associated virus 2 particles.</p

HT-PBNA inter- and intra-run variability of neutralization titers.

<p>The ED₅₀ values for HPV 16 and HPV 18 PSV of the serum standard were determined in 58 repeats on seven assay days (runs) over a period of 2 months. For six of the 7 assay days, triplicates of the standard serum dilutions were assayed 8 times each, for one assay date the standard serum was assayed 10 times.</p

Influence of PSV concentration on HT-PBNA analytical sensitivity and robustness.

<p>Neutralization titers of a serum from a Gardasil® immunized individual expressed as ED₅₀ values (open circles and open squares) with the variability (bars indicating the 95% confidence intervals) were determined at different PSV concentrations. The maximal luminescence intensities (RLU) obtained without serum are shown as crosses. An arrow indicates the dilution of the PSV preparation that was used in subsequent neutralization assays.</p

Effect of PSV-serum premix incubation time on neutralization titer.

<p>A serum from a Gardasil® vaccinated individual was pre-incubated for different times with HPV 16 or HPV 18 PSVs before the neutralization assay was initiated by the addition of reporter cells. ED₅₀ values with 95% confidence intervals are shown.</p

Titration of different PSV preparations.

<p>Serial dilution of PSV preparations from HPV types 16, 18, 31, 45, 52, 58 and BPV-1 were assayed for Gaussia luciferase activity in the HT-PBNA. For HPV types 16 and 18 a second PSV preparation is indicated by an asterisk (*). Luminescence signals are expressed as relative light units (RLU). The titers for undiluted HPV 16, 18, and BPV-1 PSV were 3.0×10⁹, 3.9×10⁹, 1.1×10¹⁰ genomes per ml, respectively.</p

Detection of neutralizing antibodies as result of natural infection by HT-PBNA.

<p>Thirty-five pre-vaccination sera from a study involving patients with CIN2+ lesions were tested for neutralizing antibodies against PSVs of HPV types 16, 18 and 31. The geometrical mean titer for each HPV type is indicated as a horizontal line and the cut off value (ED₅₀ = 80) as a dashed line.</p

Analytical sensitivity and type-specificity of the HPV 16 and HPV 18 HT-PBNA.

<p>Titration of the WHO International Standards for antibodies to HPV 16 (left) and HPV 18 (right) in HT-PBNA using PSV of HPV types 16, 18, 31, 45, 52, 58 and BPV-1.</p

Comparison of HPV 16 HT-PBNA (Gaussia) with manPBNA (SEAP and Gaussia) and GST-HPV 16 L1 antibody binding assay for natural and vaccine-induced HPV16-specific responses.

<p>HPV 16 HT-PBNA (A–D), manPBNA using SEAP reporter (A and B; titers, ED₅₀) and a bead-based GST-HPV 16 L1 antibody binding assay (C and D; median fluorescent intensity (MFI) at 1∶100 or 1∶2700 serum dilution) were used to determine reactivity of pre- (n = 35; A and C) and post-vaccination (n = 72; B and D) sera. Serum samples analyzed were from women with HPV 16 positive, high-grade cervical intraepithelial neoplasia (base-line sera of the chimeric HPV 16 L1-E7 vaccination trial). Cut off values used for positive/negative classification (broken lines in C) were an ED₅₀ of 80 for the HT-PBNA and 109 MFI at 1∶100 for the GST-L1 antibody binding assay.</p

Automated High-Throughput RNAi Screening in Human Cells Combined with Reporter mRNA Transfection to Identify Novel Regulators of Translation

<div><p>Proteins that promote angiogenesis, such as vascular endothelial growth factor (VEGF), are major targets for cancer therapy. Accordingly, proteins that specifically activate expression of factors like VEGF are potential alternative therapeutic targets and may help to combat evasive resistance to angiogenesis inhibitors. VEGF mRNA contains two internal ribosome entry sites (IRESs) that enable selective activation of VEGF protein synthesis under hypoxic conditions that trigger angiogenesis. To identify novel regulators of VEGF IRES-driven translation in human cells, we have developed a high-throughput screening approach that combines siRNA treatment with transfection of a VEGF-IRES reporter mRNA. We identified the kinase MAPK3 as a novel positive regulator of VEGF IRES-driven translation and have validated its regulatory effect on endogenous VEGF. Our automated method is scalable and readily adapted for use with other mRNA regulatory elements. Consequently, it should be a generally useful approach for high-throughput identification of novel regulators of mRNA translation.</p> </div

HT-PBNA protocol.

<p>Assay plate preparation (A) and neutralization assay (B) are separated. In a first step, serial dilutions of serum samples are performed on one dilution plate. Identical assay plates are generated by transferring the dilutions to multiple replica-assay plates which can be stored at −20°C. In the second step, the neutralization assay is carried out in a add-on format using the previously prepared assay plates. <b>A) Assay plate preparation</b>. Sera are transferred from a 96 well storage in SBS standard to a 384 well polypropylene V-bottom plate for serial dilution with a pipetting robot in cell culture medium. Finally the serially diluted sera are transferred with the same pipetting robot to each of 3*n white 384 well cell culture assay plates (n = number of PV-types). The plates are sealed immediately with a cover foil and stored at −20°C until their use in the PBNA. <b>B) Assay assembly and read out</b>. Assay plates are thawed and pseudovirions followed by reporter cells are added with a bulk dispenser. Three identical assay plates originating from the same serum dilution plate are used for each PV- type. After 2 days of incubation the luminescence from the Gaussia reporter is read directly in the assay plates. Inhibition (%) is calculated by normalization of the luminescence to the mean of the negative control wells without serum present on each plate. The median of the triplicate values is used for the calculation of the ED₅₀-value (effective dilution giving 50% inhibition) for each serum according to the four parameter logistic curve fit model y = A+(B−A)/(1+(C/x)^∧D).</p